Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Tenofovir Disoproxil on Mother-to-child Transmission of HBV (TOPCHIB)
NCT05403047Phase 4Active, not recruiting
- Sponsor
- ANRS
- Start
- Aug 2023
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tenofovir disoproxil fumarate in hepatitis B (HBV), sponsored by ANRS. Primary endpoint: Proportion of children with HBsAg positive at 48 weeks. Started Aug 2023; status: active, not recruiting.
02
Drugs
tenofovir disoproxil fumarate
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT05403047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05403047.